Animas Vibe System
Animas
FDA Clearance Information
The Animas Vibe System received FDA clearance through the PMA pathway on June 1, 2016. Manufactured by Animas, it is classified as a Class 3 medical device.
What It Is
FDA-Cleared Indications
- The Animas Vibe System includes the Dexcom G4 Platinum Sensors as a component of the system.
- The FDA record documents a change in the location of complaint-return and investigation operations for Dexcom G4 Platinum Sensors from Dexcom's San Diego facility to Animas's West Chester facility.
Clinical Applications
- Continuous subcutaneous insulin delivery for patients requiring intensive insulin therapy.
- Continuous glucose monitoring using the integrated Dexcom G4 Platinum Sensor.
- Supporting blood-glucose management in people with diabetes using insulin-pump therapy.
Evidence Summary
Reported Outcomes
Safety Profile
Evidence Limitations
Practical Considerations
- The system combines an insulin pump with a compatible Dexcom G4 Platinum continuous glucose sensor; components are not universally interchangeable with newer CGM systems.
- The pump and sensor require user training, regular glucose monitoring, insulin-reservoir and infusion-set changes, and attention to alarms and sensor readings.
- The device is not a substitute for prescribed glucose checks or clinical follow-up, particularly when symptoms do not match the sensor reading.
- MRI, CT, diathermy, and other procedures involving strong magnetic or electromagnetic fields require checking the applicable device and sensor instructions before use; the pump or sensor may need to be removed.
- The device is an older system, and availability of pumps, sensors, transmitters, infusion sets, technical support, and replacement parts may be limited.
Frequently Asked Questions
What are the clinical indications for Animas Vibe System?
The Animas Vibe System is indicated for use in patients with type 1 diabetes to improve glycemic control through integrated insulin delivery and continuous glucose monitoring.
What outcomes have been reported in clinical studies?
Studies have reported improvements in glycemic control, including reductions in HbA1c levels, and enhanced patient satisfaction with the Animas Vibe System.
What complications have been reported?
Safety data indicate potential technical difficulties with the insulin pump and electromagnetic interference with other devices, but these are consistent with other insulin pump systems.